Form D · Pharmaceuticals
ESTRIGENIX THERAPEUTICS, INC.
Wauwatosa, WI · CIK 0002141466
Offering snapshot reported Jul 27, 2026 · SEC filing
- Reported sold
- $1M Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $150K Reported outside-investor minimum
- First sale
- Jul 17, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 27, 2026 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-592228
Source: Form D, filed Jul 27, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William Donaldson | Director, Executive |
| Karyn Frick | Executive |
| Patricia Scheller | Director |
| Daniel Sem | Director, Executive |
| Victoria Zellmer | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1225 Discovery Pkwy Unit 255 C
Wauwatosa, WI, 53226
Phone: (262) 409-1484
Wauwatosa, WI, 53226
Phone: (262) 409-1484